Menu
Not yet recruiting NCT07079306

ChatGPT-Supported Text Messaging Program for Smoking Cessation

No phase Interventional Smoking Cessation

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: BeFree+Bot, BeFree.
Who it may be relevant to
Registry conditions: Smoking Cessation. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Engagement and Satisfaction With a ChatGPT-Supported Text Messaging Program for Smoking Cessation

Overview

The current research proposal aims to explore how a purpose driven LLM ChatGPT chatbot, BeFreeBot, might enhance an evidence-based text messaging smoking cessation program, BeFree. The research will consist of a formative evaluation comparing quitting related outcomes among users of BeFree+Bot and BeFree.

Interventions

  • Behavioral BeFree+Bot
    Text messaging program called BeFree and access to BBot, ChatGPT chatbot
  • Behavioral BeFree
    Text messaging program called BeFree

Primary outcome measures

  • Continuous abstinence [Time frame: at 1 month follow-up]

Eligibility criteria

Inclusion criteria

  • lives in the US
  • smoked a cigarette within the last 7 days
  • has a mobile phone
  • willing to receive text messages about the health effects of smoking on their mobile phone for 30 days

Exclusion criteria

  • none

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

United States · 1 center
  • Prolific — Washington D.C.

Identifiers

NCT: NCT07079306 · GWUniversity

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗